These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

901 related items for PubMed ID: 17507924

  • 1. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F, Armuzzi A, De Pascalis B, Mores N, Tesauro M, Melina D, Cardillo C.
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [Abstract] [Full Text] [Related]

  • 2. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis.
    Cardillo C, Schinzari F, Mores N, Mettimano M, Melina D, Zoli A, Ferraccioli G.
    Clin Pharmacol Ther; 2006 Sep; 80(3):275-81. PubMed ID: 16952494
    [Abstract] [Full Text] [Related]

  • 3. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J, López-Larrea C, González S, Fuentes D, Dieguez A, Deschamps EM, Pérez-Pariente JM, López-Vázquez A, de Francisco R, Rodrigo L.
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [Abstract] [Full Text] [Related]

  • 4. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
    Pierik M, Vermeire S, Steen KV, Joossens S, Claessens G, Vlietinck R, Rutgeerts P.
    Aliment Pharmacol Ther; 2004 Aug 01; 20(3):303-10. PubMed ID: 15274667
    [Abstract] [Full Text] [Related]

  • 5. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
    Niederau C, Backmerhoff F, Schumacher B, Niederau C.
    Hepatogastroenterology; 1997 Aug 01; 44(13):90-107. PubMed ID: 9058126
    [Abstract] [Full Text] [Related]

  • 6. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
    Henriksen M, Jahnsen J, Lygren I, Stray N, Sauar J, Vatn MH, Moum B, IBSEN Study Group.
    Gut; 2008 Nov 01; 57(11):1518-23. PubMed ID: 18566104
    [Abstract] [Full Text] [Related]

  • 7. Profile of soluble cytokine receptors in Crohn's disease.
    Gustot T, Lemmers A, Louis E, Nicaise C, Quertinmont E, Belaiche J, Roland S, Van Gossum A, Devière J, Franchimont D.
    Gut; 2005 Apr 01; 54(4):488-95. PubMed ID: 15753533
    [Abstract] [Full Text] [Related]

  • 8. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q, Hogezand RA, Lamers CB, Verspaget HW.
    Aliment Pharmacol Ther; 2004 Sep 01; 20(5):585-92. PubMed ID: 15339330
    [Abstract] [Full Text] [Related]

  • 9. Infliximab reverses growth hormone resistance associated with inflammatory bowel disease.
    Vespasiani Gentilucci U, Caviglia R, Picardi A, Carotti S, Ribolsi M, Galati G, Petitti T, Afeltra A, Cicala M.
    Aliment Pharmacol Ther; 2005 May 01; 21(9):1063-71. PubMed ID: 15854167
    [Abstract] [Full Text] [Related]

  • 10. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
    Miheller P, Muzes G, Zágoni T, Tóth M, Rácz K, Tulassay Z.
    Orv Hetil; 2005 Jul 10; 146(28):1477-80. PubMed ID: 16130441
    [Abstract] [Full Text] [Related]

  • 11. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease.
    Folwaczny C, Wiebecke B, Loeschke K.
    Am J Gastroenterol; 1999 Jun 10; 94(6):1551-5. PubMed ID: 10364024
    [Abstract] [Full Text] [Related]

  • 12. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F.
    Scand J Gastroenterol; 2006 Sep 10; 41(9):1064-72. PubMed ID: 16938720
    [Abstract] [Full Text] [Related]

  • 13. Circulating and mucosal concentrations of tumour necrosis factor and inhibitor(s) in chronic inflammatory bowel disease.
    Nielsen OH, Brynskov J, Bendtzen K.
    Dan Med Bull; 1993 Apr 10; 40(2):247-9. PubMed ID: 8495600
    [Abstract] [Full Text] [Related]

  • 14. A review of infliximab use in ulcerative colitis.
    Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB.
    Clin Ther; 2008 Feb 10; 30(2):223-30. PubMed ID: 18343261
    [Abstract] [Full Text] [Related]

  • 15. Increased arterial stiffness in inflammatory bowel diseases is dependent upon inflammation and reduced by immunomodulatory drugs.
    Zanoli L, Rastelli S, Inserra G, Lentini P, Valvo E, Calcagno E, Boutouyrie P, Laurent S, Castellino P.
    Atherosclerosis; 2014 Jun 10; 234(2):346-51. PubMed ID: 24732573
    [Abstract] [Full Text] [Related]

  • 16. Ultrastructural evidence of mucosal healing after infliximab in patients with ulcerative colitis.
    Fratila OC, Craciun C.
    J Gastrointestin Liver Dis; 2010 Jun 10; 19(2):147-53. PubMed ID: 20593047
    [Abstract] [Full Text] [Related]

  • 17. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease.
    Koutroubakis IE, Oustamanolakis P, Malliaraki N, Karmiris K, Chalkiadakis I, Ganotakis E, Karkavitsas N, Kouroumalis EA.
    Eur J Gastroenterol Hepatol; 2009 Mar 10; 21(3):283-8. PubMed ID: 19279474
    [Abstract] [Full Text] [Related]

  • 18. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM, Krauss N, Voll RE, Nägel A, Weidenhiller M, Konturek PC, Hahn EG, Raithel M.
    Digestion; 2008 Mar 10; 78(4):195-200. PubMed ID: 19122456
    [Abstract] [Full Text] [Related]

  • 19. Early changes in rectal nitric oxide and mucosal inflammatory mediators in Crohn's colitis in response to infliximab treatment.
    Ljung T, Axelsson LG, Herulf M, Lundberg JO, Hellström PM.
    Aliment Pharmacol Ther; 2007 Apr 15; 25(8):925-32. PubMed ID: 17402996
    [Abstract] [Full Text] [Related]

  • 20. The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease.
    Eivindson M, Grønbaek H, Skogstrand K, Thorsen P, Frystyk J, Flyvbjerg A, Dahlerup JF.
    Scand J Gastroenterol; 2007 Apr 15; 42(4):464-70. PubMed ID: 17454856
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.